Trade AstraZeneca PLC - GBP - AZNl CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.32 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.023178% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.00126% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | GBP | ||||||||
Margin | 20% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 116.78 |
Open* | 115.68 |
1-Year Change* | 11.07% |
Day's Range* | 115.38 - 117.3 |
52 wk Range | 93.99-128.29 |
Average Volume (10 days) | 1.40M |
Average Volume (3 months) | 32.52M |
Market Cap | 183.20B |
P/E Ratio | 48.79 |
Shares Outstanding | 1.55B |
Revenue | 35.22B |
EPS | 2.42 |
Dividend (Yield %) | 2.03609 |
Beta | 0.26 |
Next Earnings Date | Jul 28, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 117.28 | 1.62 | 1.40% | 115.66 | 117.40 | 115.30 |
May 31, 2023 | 116.78 | 2.22 | 1.94% | 114.56 | 117.54 | 114.30 |
May 30, 2023 | 113.22 | -4.28 | -3.64% | 117.50 | 118.28 | 113.22 |
May 26, 2023 | 116.62 | -0.10 | -0.09% | 116.72 | 118.18 | 116.10 |
May 25, 2023 | 116.08 | -0.70 | -0.60% | 116.78 | 118.08 | 115.64 |
May 24, 2023 | 116.34 | -2.04 | -1.72% | 118.38 | 119.14 | 116.34 |
May 23, 2023 | 119.79 | 0.42 | 0.35% | 119.37 | 121.71 | 118.86 |
May 22, 2023 | 119.77 | 0.22 | 0.18% | 119.55 | 120.95 | 119.55 |
May 19, 2023 | 120.21 | 0.62 | 0.52% | 119.59 | 120.61 | 119.22 |
May 18, 2023 | 119.60 | 0.11 | 0.09% | 119.49 | 120.83 | 119.49 |
May 17, 2023 | 118.62 | -2.43 | -2.01% | 121.05 | 121.69 | 118.50 |
May 16, 2023 | 120.31 | 1.10 | 0.92% | 119.21 | 120.89 | 119.21 |
May 15, 2023 | 119.80 | -0.21 | -0.17% | 120.01 | 120.49 | 119.58 |
May 12, 2023 | 119.72 | 0.56 | 0.47% | 119.16 | 120.75 | 119.06 |
May 11, 2023 | 119.12 | 0.44 | 0.37% | 118.68 | 119.87 | 118.52 |
May 10, 2023 | 117.98 | 0.00 | 0.00% | 117.98 | 118.64 | 116.92 |
May 9, 2023 | 118.74 | 1.22 | 1.04% | 117.52 | 119.28 | 117.52 |
May 5, 2023 | 118.92 | 0.90 | 0.76% | 118.02 | 118.94 | 116.98 |
May 4, 2023 | 118.34 | 0.02 | 0.02% | 118.32 | 118.66 | 117.42 |
May 3, 2023 | 118.68 | 0.24 | 0.20% | 118.44 | 118.92 | 117.66 |
AstraZeneca PLC - GBP Events
Time (UTC) | Country | Event |
---|---|---|
Monday, June 5, 2023 | ||
Time (UTC) 23:00 | Country GB
| Event AstraZeneca PLC at ASCO Investor Meeting (Virtual) AstraZeneca PLC at ASCO Investor Meeting (Virtual)Forecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Cost of Revenue, Total | 8649 | 9542 | 5270 | 4824 | 4246 |
Gross Profit | 35702 | 27875 | 21347 | 19560 | 17844 |
Total Operating Expense | 40594 | 36361 | 21455 | 21460 | 18703 |
Selling/General/Admin. Expenses, Total | 13512 | 11519 | 9338 | 8964 | 8479 |
Research & Development | 9612 | 8519 | 6094 | 5320 | 5266 |
Depreciation / Amortization | 4094 | 3044 | 1897 | 1812 | 1945 |
Unusual Expense (Income) | 4820 | 3846 | -763 | 863 | -953 |
Other Operating Expenses, Total | -93 | -109 | -381 | -323 | -280 |
Operating Income | 3757 | 1056 | 5162 | 2924 | 3387 |
Interest Income (Expense), Net Non-Operating | -815 | -819 | -716 | -766 | -775 |
Other, Net | -441 | -502 | -530 | -610 | -619 |
Net Income Before Taxes | 2501 | -265 | 3916 | 1548 | 1993 |
Net Income After Taxes | 3293 | 115 | 3144 | 1227 | 2050 |
Minority Interest | -5 | -3 | 52 | 108 | 105 |
Net Income Before Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Excl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Incl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Dilution Adjustment | 0 | 0 | |||
Diluted Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Diluted Weighted Average Shares | 1560 | 1427 | 1313 | 1301 | 1267 |
Diluted EPS Excluding Extraordinary Items | 2.10769 | 0.07849 | 2.43412 | 1.02613 | 1.70087 |
Dividends per Share - Common Stock Primary Issue | 2.89361 | 2.84245 | 2.83031 | 2.89446 | 2.74532 |
Diluted Normalized EPS | 3.8859 | 2.22705 | 1.88804 | 1.48501 | 0.85399 |
Interest Expense (Income) - Net Operating | 0 | 0 | |||
Total Extraordinary Items |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 10879 | 11207 | 10982 | 10771 | 11390 |
Revenue | 10879 | 11207 | 10982 | 10771 | 11390 |
Cost of Revenue, Total | 2053 | 2417 | 2118 | 1904 | 2279 |
Gross Profit | 8826 | 8790 | 8864 | 8867 | 9111 |
Total Operating Expense | 8330 | 10113 | 9737 | 10232 | 10512 |
Selling/General/Admin. Expenses, Total | 3196 | 3469 | 3353 | 3633 | 3057 |
Research & Development | 2299 | 2638 | 2357 | 2431 | 2186 |
Depreciation / Amortization | 954 | 1034 | 979 | 983 | 1098 |
Unusual Expense (Income) | 230 | 331 | 1002 | 1298 | 1953 |
Other Operating Expenses, Total | -402 | 224 | -72 | -17 | -61 |
Operating Income | 2549 | 1094 | 1245 | 539 | 878 |
Interest Income (Expense), Net Non-Operating | -287 | -316 | -323 | -292 | -325 |
Net Income Before Taxes | 2262 | 778 | 922 | 247 | 553 |
Net Income After Taxes | 1804 | 902 | 1642 | 360 | 388 |
Minority Interest | -1 | -1 | -2 | 0 | -2 |
Net Income Before Extra. Items | 1803 | 901 | 1640 | 360 | 386 |
Net Income | 1803 | 901 | 1640 | 360 | 386 |
Income Available to Common Excl. Extra. Items | 1803 | 901 | 1640 | 360 | 386 |
Income Available to Common Incl. Extra. Items | 1803 | 901 | 1640 | 360 | 386 |
Dilution Adjustment | |||||
Diluted Net Income | 1803 | 901 | 1640 | 360 | 386 |
Diluted Weighted Average Shares | 1560 | 1560 | 1559 | 1560 | 1561 |
Diluted EPS Excluding Extraordinary Items | 1.15577 | 0.57756 | 1.05196 | 0.23077 | 0.24728 |
Dividends per Share - Common Stock Primary Issue | 0 | 1.9694 | 0 | 0.93017 | 0 |
Diluted Normalized EPS | 1.27335 | 0.70833 | 0.99743 | 0.80833 | 1.24792 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 22593 | 26244 | 19544 | 15563 | 15591 |
Cash and Short Term Investments | 6405 | 6398 | 7992 | 6218 | 5680 |
Cash | 1411 | 1461 | 1182 | 755 | 893 |
Cash & Equivalents | 4755 | 4868 | 6650 | 4614 | 3938 |
Short Term Investments | 239 | 69 | 160 | 849 | 849 |
Total Receivables, Net | 9923 | 8795 | 5651 | 5181 | 4345 |
Accounts Receivable - Trade, Net | 7508 | 6324 | 3956 | 3813 | 2995 |
Total Inventory | 4699 | 8983 | 4024 | 3193 | 2890 |
Prepaid Expenses | 1329 | 1512 | 1735 | 865 | 1436 |
Other Current Assets, Total | 237 | 556 | 142 | 106 | 1240 |
Total Assets | 96483 | 105363 | 66729 | 61377 | 60651 |
Property/Plant/Equipment, Total - Net | 9449 | 10171 | 8917 | 8335 | 7421 |
Property/Plant/Equipment, Total - Gross | 17192 | 18495 | 17110 | 15852 | 14639 |
Accumulated Depreciation, Total | -7743 | -8324 | -8193 | -7517 | -7218 |
Goodwill, Net | 19820 | 19997 | 11845 | 11668 | 11707 |
Intangibles, Net | 39307 | 42387 | 20947 | 20833 | 21959 |
Long Term Investments | 1142 | 1237 | 1147 | 1459 | 922 |
Note Receivable - Long Term | 592 | 504 | 325 | 348 | 515 |
Other Long Term Assets, Total | 3580 | 4823 | 4004 | 3171 | 2536 |
Total Current Liabilities | 26293 | 22594 | 20307 | 18117 | 16292 |
Accounts Payable | 2550 | 2824 | 2350 | 1774 | 1720 |
Accrued Expenses | 8303 | 8079 | 4994 | 5085 | 5148 |
Notes Payable/Short Term Debt | 261 | 294 | 370 | 154 | 160 |
Current Port. of LT Debt/Capital Leases | 5281 | 1599 | 2016 | 1856 | 1594 |
Other Current Liabilities, Total | 9898 | 9798 | 10577 | 9248 | 7670 |
Total Liabilities | 59446 | 66095 | 51107 | 48250 | 48183 |
Total Long Term Debt | 23690 | 28888 | 17994 | 16217 | 17359 |
Long Term Debt | 22965 | 28134 | 17505 | 15730 | 17359 |
Capital Lease Obligations | 725 | 754 | 489 | 487 | 0 |
Deferred Income Tax | 2944 | 6206 | 2918 | 2490 | 3286 |
Minority Interest | 21 | 19 | 16 | 1469 | 1576 |
Other Liabilities, Total | 6498 | 8388 | 9872 | 9957 | 9670 |
Total Equity | 37037 | 39268 | 15622 | 13127 | 12468 |
Common Stock | 387 | 387 | 328 | 328 | 317 |
Additional Paid-In Capital | 35155 | 35126 | 7971 | 7941 | 4427 |
Retained Earnings (Accumulated Deficit) | 1495 | 3755 | 7323 | 4858 | 7724 |
Total Liabilities & Shareholders’ Equity | 96483 | 105363 | 66729 | 61377 | 60651 |
Total Common Shares Outstanding | 1549.8 | 1549.4 | 1312.67 | 1312.14 | 1267.04 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 22266 | 22593 | 20224 | 20917 | 22647 |
Cash and Short Term Investments | 6462 | 6405 | 4898 | 4887 | 5823 |
Cash & Equivalents | 6232 | 6166 | 4458 | 4817 | 5762 |
Short Term Investments | 230 | 239 | 440 | 70 | 61 |
Total Receivables, Net | 10797 | 11252 | 10061 | 9612 | 9050 |
Accounts Receivable - Trade, Net | 10289 | 10521 | 9336 | 8908 | 8683 |
Total Inventory | 4967 | 4699 | 5078 | 6220 | 7624 |
Other Current Assets, Total | 40 | 237 | 187 | 198 | 150 |
Total Assets | 96687 | 96483 | 94185 | 96579 | 100273 |
Property/Plant/Equipment, Total - Net | 9599 | 9449 | 9227 | 9627 | 10015 |
Goodwill, Net | 20001 | 19820 | 19707 | 19821 | 19963 |
Intangibles, Net | 39291 | 39307 | 39585 | 39900 | 41265 |
Long Term Investments | 1234 | 1142 | 1102 | 1180 | 1237 |
Note Receivable - Long Term | 682 | 835 | 792 | 881 | 864 |
Other Long Term Assets, Total | 3614 | 3337 | 3548 | 4253 | 4282 |
Total Current Liabilities | 24860 | 26293 | 24850 | 21815 | 22740 |
Payable/Accrued | 19210 | 19040 | 17694 | 17821 | 17864 |
Notes Payable/Short Term Debt | 568 | 261 | 584 | 636 | 724 |
Current Port. of LT Debt/Capital Leases | 3289 | 5281 | 5034 | 1746 | 1570 |
Other Current Liabilities, Total | 1793 | 1711 | 1538 | 1612 | 2582 |
Total Liabilities | 60898 | 59446 | 59051 | 60647 | 63933 |
Total Long Term Debt | 27646 | 23690 | 23681 | 27146 | 28805 |
Long Term Debt | 26916 | 22965 | 23013 | 26461 | 28081 |
Capital Lease Obligations | 730 | 725 | 668 | 685 | 724 |
Deferred Income Tax | 2795 | 2944 | 3479 | 5275 | 5626 |
Minority Interest | 22 | 21 | 20 | 19 | 19 |
Other Liabilities, Total | 5575 | 6498 | 7021 | 6392 | 6743 |
Total Equity | 35789 | 37037 | 35134 | 35932 | 36340 |
Common Stock | 387 | 387 | 387 | 387 | 387 |
Additional Paid-In Capital | 35159 | 35155 | 35137 | 35134 | 35131 |
Retained Earnings (Accumulated Deficit) | 243 | 1495 | -390 | 411 | 822 |
Total Liabilities & Shareholders’ Equity | 96687 | 96483 | 94185 | 96579 | 100273 |
Total Common Shares Outstanding | 1549.85 | 1549.8 | 1549.51 | 1549.48 | 1549.45 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 2501 | -265 | 3916 | 1548 | 1993 |
Cash From Operating Activities | 9808 | 5963 | 4799 | 2969 | 2618 |
Cash From Operating Activities | 5480 | 6530 | 3149 | 3762 | 3753 |
Non-Cash Items | 542 | 141 | -332 | -103 | -1276 |
Cash Taxes Paid | 1623 | 1743 | 1562 | 1118 | 537 |
Cash Interest Paid | 849 | 721 | 733 | 774 | 676 |
Changes in Working Capital | 1285 | -443 | -1934 | -2238 | -1852 |
Cash From Investing Activities | -2960 | -11058 | -285 | -657 | 963 |
Capital Expenditures | -2571 | -2200 | -2606 | -2460 | -1371 |
Other Investing Cash Flow Items, Total | -389 | -8858 | 2321 | 1803 | 2334 |
Cash From Financing Activities | -6823 | 3649 | -2203 | -1765 | -2044 |
Financing Cash Flow Items | -1047 | -178 | -101 | 4 | -67 |
Total Cash Dividends Paid | -4364 | -3856 | -3572 | -3592 | -3484 |
Issuance (Retirement) of Stock, Net | 29 | 29 | 30 | 3525 | 34 |
Issuance (Retirement) of Debt, Net | -1441 | 7654 | 1440 | -1702 | 1473 |
Foreign Exchange Effects | -80 | -62 | 12 | 5 | -38 |
Net Change in Cash | -55 | -1508 | 2323 | 552 | 1499 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2262 | 2501 | 1723 | 800 | 553 |
Cash From Operating Activities | 3133 | 9808 | 7410 | 4480 | 3232 |
Cash From Operating Activities | 1502 | 5480 | 4000 | 2666 | 1309 |
Non-Cash Items | -391 | 542 | 172 | 15 | -12 |
Cash Taxes Paid | 225 | 1623 | 1335 | 1006 | 228 |
Cash Interest Paid | 257 | 849 | 608 | 386 | 194 |
Changes in Working Capital | -240 | 1285 | 1515 | 999 | 1382 |
Cash From Investing Activities | -1246 | -2960 | -2711 | -968 | -168 |
Capital Expenditures | -1470 | -2571 | -2017 | -906 | -363 |
Other Investing Cash Flow Items, Total | 224 | -389 | -694 | -62 | 195 |
Cash From Financing Activities | -2031 | -6823 | -6465 | -5035 | -3740 |
Financing Cash Flow Items | -840 | -1047 | -1047 | -997 | -997 |
Total Cash Dividends Paid | -3047 | -4364 | -4364 | -2971 | -2971 |
Issuance (Retirement) of Stock, Net | 4 | 29 | 11 | 8 | 5 |
Issuance (Retirement) of Debt, Net | 1852 | -1441 | -1065 | -1075 | 223 |
Foreign Exchange Effects | -11 | -80 | -86 | -35 | -9 |
Net Change in Cash | -155 | -55 | -1852 | -1558 | -685 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5098 | 100893184 | 1200 | 2023-01-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.1999 | 65092368 | 768 | 2023-01-31 | LOW |
Capital Research Global Investors | Investment Advisor | 4.1199 | 63852512 | 752 | 2023-01-31 | LOW |
Investor AB | Private Equity | 3.3299 | 51608948 | 608 | 2023-01-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8464 | 44114976 | -1215991 | 2022-12-14 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2269 | 34514808 | 15209 | 2023-05-01 | LOW |
Capital World Investors | Investment Advisor | 1.7648 | 27351981 | 2675871 | 2022-12-14 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.2141 | 18816198 | 280706 | 2023-05-01 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.1273 | 17471628 | -78807 | 2023-05-01 | LOW |
GQG Partners, LLC | Investment Advisor | 1.0697 | 16579162 | 1036509 | 2022-12-14 | MED |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.9835 | 15243057 | -36818 | 2023-05-01 | LOW |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.6302 | 9767199 | -6522 | 2023-05-01 | LOW |
Nuveen LLC | Pension Fund | 0.6158 | 9543355 | 495683 | 2022-12-14 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5411 | 8386244 | -95567 | 2022-12-14 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.4985 | 7725827 | -10523 | 2023-05-01 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.4931 | 7642032 | 181760 | 2023-04-30 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.4919 | 7623953 | -442236 | 2023-05-01 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 0.4722 | 7318503 | -220395 | 2023-05-01 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.4707 | 7294740 | 0 | 2023-05-01 | LOW |
BlackRock Investment Management, LLC | Investment Advisor/Hedge Fund | 0.4379 | 6787247 | -85660 | 2023-03-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group535K+
Traders
87K+
Active clients monthly
$113M+
Monthly investing volume
$64M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - GBP Company profile
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.
Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Income Statement
- Annual
- Quarterly
News

USD/TRY forecast: Turkish lira under pressure from high inflation and low rates
We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.
17:07, 1 June 2023
Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 535.000+ traders worldwide that chose to trade with Capital.com